Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Academia and industry: allocating credit for discovery and development of new therapies
Jeffrey S. Flier
Jeffrey S. Flier
Published May 20, 2019
Citation Information: J Clin Invest. 2019;129(6):2172-2174. https://doi.org/10.1172/JCI129122.
View: Text | PDF
Viewpoint

Academia and industry: allocating credit for discovery and development of new therapies

  • Text
  • PDF
Abstract

Authors

Jeffrey S. Flier

×

Figure 1

Schematic representation of the drug discovery and development ecosystem.

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of the drug discovery and development ecosystem...
New insights into biology and pathophysiology are typically driven by fundamental research at academic institutions. Traditionally, such discoveries indirectly contribute to advances as industry seeks new projects and drug targets from basic research. The identification of new drug candidates and subsequent validation work are a strength of industry-led research. Efforts toward human proof-of-concept studies and clinical trials in patients often involve collaboration between industry partners, academic centers, clinical specialists, and clinical trial experts. Increasingly, hybrid models of drug development are being explored, wherein venture firms incubate startup companies internally to develop new approaches and patents, rather than licensing these from academic institutions, and then establish agreements with biopharma to further the development of the drug. Illustrated by Rachel Davidowitz.

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts